JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:522-528, doi:10.1016/j.jacc.2005.11.012 (Published online 13 January 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bolognese, L.
Right arrow Articles by Burali, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bolognese, L.
Right arrow Articles by Burali, A.

Randomized Comparison of Upstream Tirofiban Versus Downstream High Bolus Dose Tirofiban or Abciximab on Tissue-Level Perfusion and Troponin Release in High-Risk Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions

The EVEREST Trial

Leonardo Bolognese, MD, FESC*, Giovanni Falsini, MD, Francesco Liistro, MD, Paolo Angioli, MD, Kenneth Ducci, MD, Tamara Taddei, MD, Roberto Tarducci, MD, Franco Cosmi, MD, Silvia Baldassarre, MD and Antonio Burali, MD

Azienda Ospedaliera Arezzo, Arezzo, Italy.


Figure 1
View larger version (20K):

[in a new window]
  		Figure 1 Rate of Thrombolysis In Myocardial Infarction myocardial perfusion grade (TMPG) 0/1 flow stratified by glycoprotein IIb/IIIa inhibitor treatment pre-percutaneous coronary intervention (PCI) (A) and post-PCI (B). p = 0.0009 by Fisher exact test upstream tirofiban vs. high-dose bolus (HDB) vs. abciximab before PCI. p = 0.015 by Fisher exact test upstream tirofiban vs. HDB vs. abciximab after PCI.

 

Figure 2
View larger version (21K):

[in a new window]
  		Figure 2 (A) Myocardial contrast echocardiography score index (MCSEI) as a semiquantitative index of impaired tissue perfusion in the three groups of patients. p < 0.05 by analysis of variance (ANOVA) upstream tirofiban versus high-dose bolus (HDB) versus abciximab. (B) Patients perfused by myocardial contrast echocardiography (MCE) among the three therapeutic regimen groups. p = 0.04 by ANOVA upstream tirofiban vs. HDB vs. abciximab.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.